NATURAL PSYCHODYSLEPTIC COMPOUNDS: SOURCES AND PHARMACOLOGY

Sisira Padavala; Ezhilarasan Devaraj

doi:10.22159/ajpcr.2016.v9i5.13345

Authors

Sisira Padavala Bachelor of Dental Surgery, Saveetha Dental College and Hospitals, Saveetha University, Chennai, Tamil Nadu, India -600 077 E- mail: sisira_padavala@yahoo.co.uk Mobile: 9789258183
Ezhilarasan Devaraj Assistant Professor, Saveetha Dental College and Hospitals, Saveetha University, Chennai, Tamil Nadu, India -600 077 E- mail: ezhild@gmail.com Phone: (Off) 044-26801580-87 Mobile: 9944008201

DOI:

https://doi.org/10.22159/ajpcr.2016.v9i5.13345

Abstract

Compounds in some plants have remarkable effects on the central nervous system. Plants containing those compounds are mind altering or
psychoactive in nature. These are consumed in the form of simple or complex preparations to affect the mind or alter the state of consciousness.
Psychoactivity may include sedative, stimulant, euphoric, deliriant, and hallucinogenic effects. Several hundred psychoactive plants are known.
Some important examples of psychoactive plants include Datura, Salvia, and Cannabis. Psychoactive plants have been used ritually, medicinally, and
recreationally for thousands of years. Hence, the sociocultural and economic significance of psychoactive plants is enormous.
Keywords: Cannabis, Datura, Psychoactive plants, Euphoria, Hallucinogen.

Downloads

Download data is not yet available.

References

Freeman D, Dunn G, Murray RM, Evans N, Lister R, Antley A, et al. How cannabis causes paranoia: Using the intravenous administration of Î”9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull 2015;41(2):391-9.

Cho CM, Hirsch R, Johnstone S. General and oral health implications of cannabis use. Aust Dent J 2005;50(2):70-4.

Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 2011;5(1):1-8.

Battistella G, Fornari E, Annoni JM, Chtioui H, Dao K, Fabritius M, et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology 2014;39(9):2041-8.

Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330(7481):11.

Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: Cohort study. BMJ 2002;325(7374):1195-8.

Malone DT, Hill MN, Rubino T. Adolescent cannabis use and psychosis: Epidemiology and neurodevelopmental models. Br J Pharmacol 2010;160(3):511-22.

Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 2001;25(5):757-65.

Jouanjus E, Lapeyre-Mestre M, Micallef J; French Association of the Regional Abuse and Dependence monitoring centres (CEIP-A) working group on cannabis complications*. cannabis use: Signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc 2014;3(2):e000638.

Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain 2013;14(2):136-48.

Mikaszewska-Sokolewicz MA, Pankowska S, Janiak M, Pruszczyk P, Lazowski T, Jankowski K. Coma in the course of severe poisoning after consumption of red fly agaric (Amanita muscaria). Acta Biochim Pol 2016;63(1):181-2.

Fraser PJ. Pharmacological actions of pure muscarine chloride. Br J Pharmacol Chemother 1957;12(1):47-52.

Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 2012;109(6):2138-43.

Johnson MW, Sewell RA, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend 2012;123(1-3):132-40.

Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 1999;20(6):565-81.

Musha M, Ishii A, Tanaka F, Kusano G. Poisoning by hallucinogenic mushroom hikageshibiretake (Psilocybe argentipes K. Yokoyama) indigenous to Japan. Tohoku J Exp Med 1986;148(1):73-8.

Benjamin C. Persistent psychiatric symptoms after eating psilocybin mushrooms. Br Med J 1979;1(6174):1319-20.

OsÃ³rio Fde L, Sanches RF, Macedo LR, Santos RG, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Rev Bras Psiquiatr 2015;37(1):13-20.

Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 2003;306(1):73-83.

Riba J, Anderer P, Morte A, Urbano G, JanÃ© F, Saletu B, et al. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br J Clin Pharmacol 2002;53(6):613-28.

Bouso JC, GonzÃ¡lez D, Fondevila S, Cutchet M, FernÃ¡ndez X, Ribeiro Barbosa PC, et al. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: A longitudinal study. PLoS One 2012;7(8):e42421.

MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR. Dose-related effects of salvinorin A in humans: Dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl) 2013;226(2):381-92.

Listos J, Merska A, Fidecka S. Pharmacological activity of salvinorin A, the major component of Salvia divinorum. Pharmacol Rep 2011;63(6):1305-9.

Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012;8(1):15-32.

Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR. Human psychopharmacology and dose-effects of Salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 2011;115(1-2):150-5.

Winslow M, Mahendran R. From divination to madness: Features of acute intoxication with Salvia use. Singapore Med J 2014;55(4):e52-3.

Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS. Pharmacokinetics of the potent hallucinogen, Salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neuroimage 2008;41(3):1044-50.

Kurzbaum A, Simsolo C, Kvasha L, Blum A. Toxic delirium due to Datura stramonium. Isr Med Assoc J 2001;3(7):538-9.

Soni P, Siddiqui AA, Dwivedi J, Soni V. Pharmacological properties of Datura stramonium L. as a potential medicinal tree: An overview. Asian Pac J Trop Biomed 2012;2(12):1002-8.

Belton PA, Gibbons DO. Datura intoxication in West Cornwall. Br Med J 1979;1(6163):585-6.

Adegoke SA, Alo LA. Datura stramonium poisoning in children. Niger J Clin Pract 2013;16(1):116-8.

Charpin D, Orehek J, Velardocchio JM. Bronchodilator effects of antiasthmatic cigarette smoke (Datura stramonium). Thorax 1979;34(2):259-61.